Abstract
We transplanted six solid organs from three hepatitis C virus (HCV) polymerase chain reaction (PCR)-positive donors during 2018–2023. Recipients were treated with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir for 4–12 weeks, with all six achieving sustained virological response without significant adverse events. As occurs in other jurisdictions, solid organ transplants from HCR PCR-positive donors can be safely utilised in Australia.
Original language | English |
---|---|
Pages (from-to) | 678-681 |
Number of pages | 4 |
Journal | Internal Medicine Journal |
Volume | 54 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2024 |